LGND News Alert Ligand Pharmaceuticals Inc (LGND) 52.52 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 4:33 AM

Ligand Pharmaceuticals Inc (LGND) 52.52 $LGND

Ligand Pharmaceuticals: Investor Day Highlights The Big 6, All Undervalued Catalysts
Chris Katje - at Seeking Alpha - Mon Nov 24, 8:04AM CST

LGND: 52.52 (-1.37)

Ligand Provides Highlights from Today's Analyst Day Event
Business Wire - Tue Nov 18, 10:41AM CST
At an Analyst Day event held earlier today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the financial leverage in its business model, revenue growth opportunities and its portfolio of partnered assets and unpartnered development programs, as well as its Captisol formulation technology and its financial outlook through 2017.
LGND: 52.52 (-1.37)

Ligand Pharmaceuticals Shares Up 17.2% Since SmarTrend's Buy Recommendation (LGND)
Comtex SmarTrend(R) - Tue Nov 18, 9:44AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 1 month, Ligand Pharmaceuticals has returned 17.21% as of today's recent price of $57.25.
LGND: 52.52 (-1.37)

Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:00PM CST
Ligand Pharma (LGND) announced the submission of a Marketing Authorisation Application to the European Medicines Agency by its partner GlaxoSmithKline for Revolade.
LGND: 52.52 (-1.37), ILMN: 184.30 (-2.53), GSK: 42.42 (-0.93), CELG: 114.49 (-2.25)

Glaxo applies for Revolade label expansion in Europe
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:01AM CST

LGND: 52.52 (-1.37), GSK: 42.42 (-0.93)

Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade(TM) (eltrombopag)
Business Wire - Wed Nov 12, 8:15AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for Revolade(TM) (eltrombopag), seeking an additional indication for the treatment of adult patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).
LGND: 52.52 (-1.37), GSK: 42.42 (-0.93)

Shares of LGND Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 11, 9:22AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 4 weeks, Ligand Pharmaceuticals has returned 13.91% as of today's recent price of $55.64.
LGND: 52.52 (-1.37)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), LGND: 52.52 (-1.37), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST

JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), LGND: 52.52 (-1.37), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)

Post Earnings Update: Ligand Pharmaceuticals Has Sunk 0.5% Lower in Past 2 Weeks (LGND)
Comtex SmarTrend(R) - Mon Nov 10, 11:52AM CST
When Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings 14 days ago on October 27th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $14.9 million. The company actually reported EPS of $0.06 on sales of $15.0 million, missing EPS estimates by $0.27 and matching revenue estimates. Shares of Ligand Pharmaceuticals have slipped from $54.23 to $53.94, representing a loss of 0.5%, since the company reported earnings 14 days ago.
LGND: 52.52 (-1.37)

Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST

JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), LGND: 52.52 (-1.37), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)

Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST

JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), LGND: 52.52 (-1.37), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)

Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST

JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), LGND: 52.52 (-1.37), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)

Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST

JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), LGND: 52.52 (-1.37), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)

Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 344.49 (+2.16), LGND: 52.52 (-1.37), AMGN: 164.53 (-1.55), GSK: 42.42 (-0.93)

Ligand Pharmaceuticals Has Rich A Valuation Now But Is Undervalued For Long Term Success
Chris Katje - at Seeking Alpha - Wed Oct 29, 10:34AM CDT

PFE: 30.95 (-0.70), AZN: 71.80 (-1.80), LGND: 52.52 (-1.37), AMGN: 164.53 (-1.55), GSK: 42.42 (-0.93)

Update: Ligand Posts Consecutive Earnings Beat
Trevor Lowenthal - at Seeking Alpha - Tue Oct 28, 3:21PM CDT

LGND: 52.52 (-1.37)

Ligand Pharmaceuticals' (LGND) CEO Steve Holmes on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Oct 27, 1:56PM CDT

LGND: 52.52 (-1.37)

Ligand Pharmaceuticals reaffirms full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:31AM CDT

LGND: 52.52 (-1.37)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Unlock Ingenuity Hits Georgia: Homeowners Rejoice

A Game-Changer for Georgia Homeowners Georgia, your ship might just have come in. The Unlock Home Equity Agreement (HEA) has cornered the market by letting homeowners dip into their home's cash pool without touching their wallets for monthly payments. This means cash in your hands now, in exchange for a share of the home's future value when you decide to wrap it up. It's...

Frasle Mobility's Resilience Despite Market Woes in 3Q26

Economic Wrangling: What Happened? Here comes Frasle Mobility, standing tall against a tide trying to pull everyone under. Ending the third quarter of 2026, they dropped a modest net revenue of R$1.38 billion. A light dip of 1.9% year-over-year, but don't let that fool you. Amid the chaos, these folks managed to expand their gross margin and kept their financials...

SoLo Alpha: Transforming Retail Investment Returns

Pushing Beyond Traditional Financial Constructs In a world where the average Joe is often left holding the short end of the investment stick, SoLo Funds comes charging through with SoLo Alpha, touting a whopping 16% annualized return. They're riding a wave of what seems like a financial revolution, serving up high returns usually reserved for the big fish. It’s hard not...

MyyShop Poised to Redefine the Creator Economy

Breaking Ground in Creator Ecosystems MyyShop isn't just a player in the creator economy; it's trying to change the damned rules. By focusing intensely on co-creation and learning, MyyShop's putting its chips on creating an inclusive and sustainable space where creators aren't just participants but the ones calling the shots. Catalyzing Co-Creation Everybody in the game...

FIS Under Investigation: Legal Woes Hit Shareholders

When Forecasts Falter: A Reality Check for FIS Investors You ever get the feeling a company is just a bit too optimistic? Well, Fidelity National Information Services, Inc. (NYSE: FIS) might've been playing that game up until its recent fiscal hiccup. The mess started on November 4, 2026, when FIS decided to slash its fiscal 2026 adjusted EPS outlook. From a Wall Street...

Medically Supervised Weight Loss: An In-Depth View

Understanding Medical Weight Loss You know, it's high time folks realize that losing weight ain't just about skipping dessert or jogging until you drop. Susan Stivalo, a specialist from Advanced Health and Aesthetics, knows the doughnut from the hole when it comes to tackling weight through medication. The HelloNation article breaks it down: medical weight loss is a...

M-tron Industries Delivers Robust Q3 2026 Performance

Key Takeaways from M-tron's Q3 Results Well, M-tron Industries just put out numbers for Q3 2026 that’ve got the street buzzing. With 11.1% growth in revenues, their top-line performance ain't something to sniff at, especially when the defense and aerospace sectors drive the engine. They're not just coasting on momentum—there's some solid guidance here, with a backlog...

Huawei Shakes Up Home Energy With LUTERRA S2

Welcome to the Future of Home Energy If you thought home energy systems couldn't get any slicker, Huawei's got news for you. They just dropped the LUTERRA S2, a swanky, all-in-one residential energy system that's about to put your old setup to shame. This ain’t your granddad's inverter. We're talking hybrid functionality with storage and AI-driven energy management...

Goranson Bain Ausley Welcomes Marichalar: Family Law Focus

Strengthening San Antonio's Family Law Field Brenda Marichalar is joining the ranks at Goranson Bain Ausley (GBA) with a reputation built on solid courtroom chops and a knack for making clients feel like they’re more than just case numbers. She’s landing right in San Antonio, a region that’s not just about the riverwalks and missions, but about real families...

DFRobot & Sensirion Unveil Cutting-Edge Formaldehyde Sensor

Game-Changing Sensor Technology Hits the Market It's not every day that two heavyweights team up and deliver something that might just shake up an entire sector. That's exactly what's happening with DFRobot and Sensirion's latest joint venture. Launching the SFA40 Formaldehyde Module, these companies are getting down and dirty with air quality detection like never before....